ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
Acerta Pharma BV
Acerta Pharma BV
Memorial Sloan Kettering Cancer Center
Gilead Sciences
Chinese PLA General Hospital
Fred Hutchinson Cancer Center
Chinese PLA General Hospital
UNC Lineberger Comprehensive Cancer Center
Chinese PLA General Hospital
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Asan Medical Center
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center